Phase III randomized trial of surgery with or without intraoperative photodynamic therapy and postoperative immunochemotherapy for malignant pleural mesothelioma

Pass, Harvey I.; Temeck, Barbara K.; Kranda, Karen; Thomas, Gunther; Russo, Angelo; Smith, Paul D.; Friauf, Walter S.; Steinberg, Seth M.

doi:10.1007/bf02303746

Cited by 182 publications

(110 citation statements)

References 12 publications

Supporting

Mentioning

106

Contrasting

Unclassified

Order By: Relevance

“…36 Also excluded was a study where patients having 'maximum debulking surgery' either EPP or PD and complex adjuvant therapy were randomized, half having photodynamic therapy. 37 As the purpose of that study was evaluation of photodynamic therapy and the surgery was mixed it was excluded from our analysis. However, other studies with primary intent of reporting one or more adjuvant therapies were included if they also included data in lung sparing surgery which could be analysed.…”

Section: Discussionmentioning

confidence: 99%

A systematic review of lung-sparing extirpative surgery for pleural mesothelioma

et al. 2011

View full text Add to dashboard Cite

SummaryObjectives There is a resurgence of interest in lung-sparing extirpative surgery for malignant pleural mesothelioma with recent reports of better survival and fewer adverse consequences than with extrapleural pneumonectomy. However, these operations are not well-characterized and to offer evidence-based clinical recommendations and to plan future trials a summary of what is already known is required.Design A formal literature search was performed and all recovered titles were sequentially sifted by title, abstract and full-text reading according to prespecified criteria. Papers were selected if they contained data relevant to the area of enquiry. Quantitative synthesis and textual analysis, appropriate to the material, were performed.Setting Follow-up studies of patients undergoing surgery for malignant pleural mesothelioma in specialist thoracic or cardiothoracic units.Participants Among the operated patients described in these papers, a total of 1270 patients had undergone lung-sparing surgery for mesothelioma.Results There were no randomized trials or other forms of controlled studies. From 464 titles, 26 papers contained sufficient data on 1270 patients to be included in the systematic review. Operative descriptions for all series were extracted and tabulated and variation was found in the nature of surgery within and between series, and the degree of detail with which it was described. There was more operative detail in recent papers. All available numerical data were extracted, tabulated and summarized using quantitative methods. The average survival at 1, 2, 3, 4 and 5 years was 51%, 26%, 16%, 11% and 9%, respectively. There were no data on patients' performance status, symptomatic change, or other patient reported outcomes.

show abstract

Section: Discussionmentioning

confidence: 99%

A systematic review of lung-sparing extirpative surgery for pleural mesothelioma

et al. 2011

View full text Add to dashboard Cite

show abstract

“…Diffuse malignant pleural mesothelioma is an uncommon and lethal cancer for which there is currently no universally accepted treatment standard (1)(2)(3)(4). The incidence of malignant mesothelioma is estimated at 2000-3000 cases annually in the USA (5).…”

Section: Introductionmentioning

confidence: 99%

Soluble mesothelin related peptides (SMRP) and osteopontin as protein biomarkers for malignant mesothelioma: analytical validation of ELISA based assays and characterization at mRNA and protein levels

Alex

Flores

Mathew

et al. 2010

Clinical Chemistry and Laboratory Medicine

View full text Add to dashboard Cite

Background: There is a need to identify reliable markers for malignant mesothelioma. Soluble mesothelin related peptides (SMRP) and osteopontin (OPN) have gained interest in recent years for this purpose. Methods: SMRP (Fujirebio Diagnostics Inc.) and OPN (R&D Inc.) ELISA methods were evaluated for multiple parameters. Concentrations were measured in blood from patients with mesothelioma, normal healthy volunteers, and patients with other (non-mesothelioma) cancers. In silico analysis was performed using the GeoProfiles database. At the protein level, SMRP and OPN were measured in cell culture supernatants, and values were compared in patients pre-and post-extrapleural pneumonectomy. Results: The SMRP assay demonstrates intra-assay CVs of 2.3% and 3% (at 4.6 nM and 13.7 nM, respectively), and inter-assay CVs of 3.5% and 3.7% at the same concentrations. The limit of detection (LOD) is 0.182 nM. The OPN assay demonstrates intra-assay CVs of 5.8%, 4.1%, and 5.2% (at 1.9, 5.1, and 11.1 ng/mL, respectively), and inter-assay CVs of 8.5%, 8.4%, and 12.1% at the same concentrations. The LOD is 0.032 ng/mL. Both SMRP and OPN in mesothelioma patients were significantly higher than in patients with other (non-mesothelioma) cancer and in healthy volunteers. The two markers do not appear to correlate with each other and exhibit different tissue expression patterns.

show abstract

“…The first phase III trial assessing the benefit of PDT for MPM was performed by Pass and colleagues from 1993 to 1996 (34). Sixty-three patients undergoing maximum debulking surgery and postoperative cisplatin, interferon alpha-2b, and tamoxifen immunochemotherapy were randomized to receive or not receive intraoperative porfimer sodium-based PDT.…”

Section: Pdtmentioning

confidence: 99%

Intraoperative adjuncts for malignant pleural mesothelioma

Chan

Sugarbaker

Burt

2017

Transl. Lung Cancer Res.

View full text Add to dashboard Cite

Malignant pleural mesothelioma (MPM) is a rapidly fatal disease. Multimodality surgically based therapies may extend survival in select patients, however, local relapse after resection is common.Novel intraoperative adjunctive therapies including heated intraoperative chemotherapy (HIOC), heated intraoperative povidone-iodine (PVP-I), and photodynamic therapy (PDT) target micrometastatic disease and aim to improve local control. This review details the most recent studies and trials of HIOC, heated intraoperative PVP-I, and PDT, this aims to provide an update on some of the most promising intraoperative adjuncts for patients with MPM.Keywords: Malignant pleural mesothelioma (MPM); heated intraoperative chemotherapy (HIOC); heated intraoperative povidone-iodine (PVP-I); photodynamic therapy (PDT)

show abstract

Phase III randomized trial of surgery with or without intraoperative photodynamic therapy and postoperative immunochemotherapy for malignant pleural mesothelioma

Abstract: Aggressive multimodal therapy can be delivered for patients with higher stage MPM. First-generation PDT does not prolong survival or increase local control for MPM.

Cited by 182 publications

References 12 publications

A systematic review of lung-sparing extirpative surgery for pleural mesothelioma

A systematic review of lung-sparing extirpative surgery for pleural mesothelioma

Soluble mesothelin related peptides (SMRP) and osteopontin as protein biomarkers for malignant mesothelioma: analytical validation of ELISA based assays and characterization at mRNA and protein levels

Intraoperative adjuncts for malignant pleural mesothelioma

Contact Info

Product

Resources

About